Efficacy and Safety of CKDB-501A in Subjects With Moderate-to-severe Glabellar Lines in Phase 3 Trial

Phase 3 Completed 300 enrolled CKD Bio Corporation

RandomizedParallel-groupDouble-blindTreatment

Summary

A Randomized, Double-blind, Active-controlled, Multi-center Phase 3 Trial to Investigate the Efficacy and Safety of CKDB-501A in Subjects with Moderated-to-severe Glabella Lines

Timeline

Start: 2023-04-13
Primary completion: 2023-08-29
Completion: 2023-11-20

Publications

Choi SY, Kim BJ, Lee YW, Kim WS, Yoon YN, Kim JS. Efficacy and Safety of CKDB-501A in Treating Moderate-To-Severe Glabellar Lines: A Randomized, Double-Blind, Active-Controlled, Multi-Center Phase III Trial. J Cosmet Dermatol. 2025 Jul;24(7):e70305. doi: 10.1111/jocd.70305.

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Botulinum toxin type A	Protein / enzyme biologic	—	Intramuscular
Subject	CKDB-501A	Protein / enzyme biologic	—	Intramuscular

Indications

No indication recorded.